---
title: "Imbruvica (ibrutinib), all indications: Safety questions"
description: "Safety questions on Imbruvica (ibrutinib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings, Monitoring, and Side effects. Questions: Does Imbruvica prolong the QT interval? What are the warnings and precautions for Imbruvica? What are the contraindications for Imbruvica? Does Imbruvica cause bleeding? 11 further questions follow. 15 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/imbruvica/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib), all indications: Safety questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)  
Indication pages: [Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)

## Safety

<a id="imbruvica-qt-interval"></a>

### Does Imbruvica prolong the QT interval?

> “At a single dose 4 times the maximum recommended dose (1680 mg), IMBRUVICA did not 
> prolong the QT interval to any clinically relevant extent.”

Source: [IMBRUVICA: Prescribing information, page 34, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=34)

## Warnings

<a id="imbruvica-warnings"></a>

### What are the warnings and precautions for Imbruvica?

> “• Hemorrhage: Monitor for bleeding and manage (5.1). 
> • Infections: Monitor patients for fever and infections, evaluate promptly, 
> and treat (5.2). 
> • Cardiac Arrhythmias, Cardiac Failure, and Sudden Death: Monitor for 
> symptoms of arrhythmias and cardiac failure and manage (5.3).  
> • Hypertension: Monitor blood pressure and treat (5.4). 
> • Cytopenias: Check complete blood counts monthly (5.5). 
> • Second Primary Malignancies: Other malignancies have occurred in 
> patients, including skin cancers, and other carcinomas (5.6). 
> • Hepatotoxicity, Including Drug-Induced Liver Injury: Monitor hepatic 
> function throughout treatment (5.7).  
> • Tumor Lysis Syndrome (TLS): Assess baseline risk and take precautions. 
> Monitor and treat for TLS (5.8). 
> • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of 
> reproductive potential of the potential risk to a fetus and to use effective 
> contraception (5.9, 8.1, 8.3).”

Source: [IMBRUVICA: Prescribing information, page 1, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=1)

<a id="imbruvica-contraindications"></a>

### What are the contraindications for Imbruvica?

> “CONTRAINDICATIONS 
> None”

Source: [IMBRUVICA: Prescribing information, page 7, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=7)

<a id="imbruvica-bleeding"></a>

### Does Imbruvica cause bleeding?

> “Fatal bleeding events have occurred in patients who received IMBRUVICA<sup>®</sup>. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA<sup>®</sup> in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA<sup>®</sup>, respectively.
>
> The mechanism for the bleeding events is not well understood.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Fatal%20bleeding%20events%20have%20occurred,events%20is%20not%20well%20understood.)

> “Inform patients of the possibility of bleeding, and to report any signs or symptoms (severe 
> headache, blood in stools or urine, prolonged or uncontrolled bleeding).”

Source: [IMBRUVICA: Prescribing information, page 53, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=53)

<a id="imbruvica-heart-problems"></a>

### Does Imbruvica cause atrial fibrillation or other heart problems?

> “Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA<sup>®</sup>. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA<sup>®</sup> in clinical trials, including in patients who received IMBRUVICA<sup>®</sup> in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events.
>
> Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA<sup>®</sup> in clinical trials, including in patients who received IMBRUVICA<sup>®</sup> in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections.
>
> Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function. Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA<sup>®</sup> treatment.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Fatal%20and%20serious%20cardiac%20arrhythmias,treatment.)

> “Cardiovascular Events 
> Data on cardiovascular events are based on randomized controlled trials with IMBRUVICA 
> (n=2,115; median treatment duration of 19.1 months for 1,157 patients treated with 
> IMBRUVICA and 5.3 months for 958 patients in the control arm). The incidence of ventricular 
> tachyarrhythmias (ventricular extrasystoles, ventricular arrhythmias, ventricular fibrillation, 
> ventricular flutter, and ventricular tachycardia) of any grade was 1.0% versus 0.4% and of Grade 
> 3 or greater was 0.3% versus 0% in patients treated with IMBRUVICA compared to patients in 
> the control arm.  The incidence of atrial fibrillation and atrial flutter of any grade was 8.4% 
> versus 1.6% and for Grade 3 or greater was 4.0% versus 0.5% in patients treated with 
> IMBRUVICA compared to patients in the control arm. In addition, the incidence of cardiac 
> failure of any grade was 1.7% versus 0.5% and for Grade 3 or greater was 1.2% versus 0.3% in 
> patients treated with IMBRUVICA compared to patients in the control arm. 
> The incidence of ischemic cerebrovascular events (cerebrovascular accidents, ischemic stroke, 
> cerebral ischemia, and transient ischemic attack) of any grade was 1% versus 0.4% and Grade 3 
> or greater was 0.5% versus 0.2% in patients treated with IMBRUVICA compared to patients in 
> the control arm, respectively.”

Source: [IMBRUVICA: Prescribing information, page 28, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=28)

<a id="imbruvica-high-blood-pressure"></a>

### Does Imbruvica cause high blood pressure?

> “Hypertension occurred in 19% of 1,476 patients with B-cell malignancies who received IMBRUVICA<sup>®</sup> in clinical trials. Grade 3 or greater hypertension occurred in 8% of patients. Based on data from a subset of these patients (N=1,124), the median time to onset was 5.9 months (range, 0 to 24 months). In a long-term safety analysis over 5 years of 1,284 patients with B-cell malignancies treated for a median of 36 months (range, 0 to 98 months), the cumulative rate of hypertension increased over time. The prevalence for Grade 3 or greater hypertension was 4% (year 0-1), 7% (year 1-2), 9% (year 2-3), 9% (year 3-4), and 9% (year 4-5); the overall incidence for the 5-year period was 11%. Monitor blood pressure in patients treated with IMBRUVICA<sup>®</sup>, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA<sup>®</sup> as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Hypertension%20occurred%20in%2019%25%20of,Grade%203%20or%20higher%20hypertension.)

<a id="imbruvica-infections"></a>

### How common are serious infections with Imbruvica?

> “Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA<sup>®</sup> therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients with B-cell malignancies who received IMBRUVICA<sup>®</sup> in clinical trials. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA<sup>®</sup>. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Fatal%20and%20non%2Dfatal%20infections%20%28including,and%20infections%20and%20treat%20appropriately.)

> “• Infections: hepatitis B reactivation”

Source: [IMBRUVICA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=29)

<a id="imbruvica-second-cancers"></a>

### How common are second cancers, including skin cancer, with Imbruvica?

> “Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients with B-cell malignancies who received IMBRUVICA<sup>®</sup> in clinical trials. The most frequent second primary malignancy was non-melanoma skin cancer (6%).”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Other%20malignancies%20%2810%25%29%2C%20including%20non%2Dskin,was%20non%2Dmelanoma%20skin%20cancer%20%286%25%29.)

<a id="imbruvica-liver"></a>

### Can Imbruvica cause liver damage?

> “Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including IMBRUVICA<sup>®</sup>. Evaluate bilirubin and transaminases at baseline and throughout treatment with IMBRUVICA<sup>®</sup>. For patients who develop abnormal liver tests after IMBRUVICA<sup>®</sup>, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold IMBRUVICA<sup>®</sup>. Upon confirmation of DILI, discontinue IMBRUVICA<sup>®</sup>”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Hepatotoxicity%2C%20including%20severe%2C%20life%2Dthreatening%2C%20and,Upon%20confirmation%20of%20DILI%2C%20discontinue)

> “• Hepatobiliary disorders: hepatic failure including acute and/or fatal events, hepatic 
> cirrhosis, drug-induced liver injury”

Source: [IMBRUVICA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=29)

> “Inform patients that liver problems, including drug-induced liver injury and abnormalities in 
> liver tests, may develop during IMBRUVICA treatment. Advise patients to contact their 
> healthcare provider immediately if they experience abdominal discomfort, dark urine, or 
> jaundice”

Source: [IMBRUVICA: Prescribing information, page 54, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=54)

<a id="imbruvica-tumor-lysis-syndrome"></a>

### Can Imbruvica cause tumor lysis syndrome?

> “Tumor lysis syndrome has been infrequently reported with IMBRUVICA<sup>®</sup>. Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=Tumor%20lysis%20syndrome%20has%20been,closely%20and%20treat%20as%20appropriate.)

## Monitoring

<a id="imbruvica-blood-counts"></a>

### How often should blood counts be checked on Imbruvica?

> “In 645 patients with B-cell malignancies who received IMBRUVICA<sup>®</sup> as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 2.8%, based on laboratory measurements. Monitor complete blood counts monthly.”

Source: [IMBRUVICA: Warnings & Precautions - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/safety/warnings-and-precautions#:~:text=In%20645%20patients%20with%20B%2Dcell,Monitor%20complete%20blood%20counts%20monthly.)

<a id="imbruvica-monitoring"></a>

### What monitoring is needed during Imbruvica treatment?

> “Monitor for bleeding and manage
> Monitor patients for fever and infections, evaluate promptly, and treat
> Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function
> Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines, and consider the risks and benefits of continued IMBRUVICA<sup>®</sup> treatment. See Dosage and Administration. See Dosage Modifications
> Monitor blood pressure and initiate or adjust antihypertensive medication as appropriate and follow dosage modification guidelines for Grade 3 or higher hypertension
> Check complete blood counts monthly for cytopenias
> Advise patients that other malignancies have occurred in patients, including skin cancers and other carcinomas
> Hepatotoxicity, including drug-induced liver injury, may occur; monitor hepatic function throughout treatment
> Assess baseline risk for tumor lysis syndrome. Take precautions, monitor, and treat
> Advise women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy
> Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA<sup>®</sup> and for 1 month after the last dose
> Advise males with female partners of reproductive potential to use effective contraception during treatment with IMBRUVICA<sup>®</sup> and for 1 month after the last dose
> Advise women not to breastfeed during treatment with IMBRUVICA<sup>®</sup> and for 1 week after the last dose”

Source: [IMBRUVICA: Patient Monitoring - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/patient-monitoring#:~:text=Monitor%20for%20bleeding%20and%20manage,week%20after%20the%20last%20dose)

## Side effects

<a id="imbruvica-diarrhea"></a>

### How common is diarrhea with Imbruvica?

> “Diarrhea 
> In randomized controlled trials (n=2,115; median treatment duration of 19.1 months for 
> 1,157 patients treated with IMBRUVICA and 5.3 months for 958 patients in the control arm), 
> diarrhea of any grade occurred at a rate of 43% of patients treated with IMBRUVICA compared 
> to 19% of patients in the control arm. Grade 3 diarrhea occurred in 3% versus 1% of 
> IMBRUVICA-treated patients compared to the control arm, respectively. Less than 1% (0.3%) 
> of subjects discontinued IMBRUVICA due to diarrhea compared with 0% in the control arm. 
> Based on data from 1,605 of these patients, the median time to first onset was 21 days (range, 0 
> to 708) versus 46 days (range, 0 to 492) for any grade diarrhea and 117 days (range, 3 to 414) 
> versus 194 days (range, 11 to 325) for Grade 3 diarrhea in IMBRUVICA-treated patients 
> compared to the control arm, respectively. Of the patients who reported diarrhea, 85% versus”

Source: [IMBRUVICA: Prescribing information, page 28, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=28)

> “89% had complete resolution, and 15% versus 11% had not reported resolution at time of 
> analysis in IMBRUVICA-treated patients compared to the control arm, respectively.”

Source: [IMBRUVICA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=29)

> “Advise patients that they may experience loose stools or diarrhea and should contact their doctor 
> if their diarrhea persists. Advise patients to maintain adequate hydration”

Source: [IMBRUVICA: Prescribing information, page 55, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=55)

Note: The first two passages are consecutive text across pages 28 and 29 of the Prescribing Information.

<a id="imbruvica-blurred-vision"></a>

### Can Imbruvica cause blurred vision?

> “Visual Disturbance 
> In randomized controlled trials (n=2,115; median treatment duration of 19.1 months for 
> 1,157 patients treated with IMBRUVICA and 5.3 months for 958 patients in the control arm), 
> blurred vision and decreased visual acuity of any grade occurred in 11% of patients treated with 
> IMBRUVICA (9% Grade 1, 2% Grade 2, no Grade 3 or higher) compared to 6% in the control 
> arm (5% Grade 1 and < 1% Grade 2 and 3).  
> Based on data from 1,605 of these patients, the median time to first onset was 91 days (range, 0 
> to 617) versus 100 days (range, 2 to 477) in IMBRUVICA-treated patients compared to the 
> control arm, respectively. Of the patients who reported visual disturbances, 60% versus 71% had 
> complete resolution and 40% versus 29% had not reported resolution at the time of analysis in 
> IMBRUVICA-treated patients compared to the control arm, respectively.  The median time from 
> onset to resolution was 37 days (range, 1 to 457) versus 26 days (range, 1 to 721) in 
> IMBRUVICA-treated subjects compared to the control arm, respectively.”

Source: [IMBRUVICA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=29)

<a id="imbruvica-postmarketing-side-effects"></a>

### What side effects of Imbruvica have been reported after approval?

> “The following adverse reactions have been identified during postapproval use of IMBRUVICA. 
> Because these reactions are reported voluntarily from a population of uncertain size, it is not 
> always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure. 
> • Hepatobiliary disorders: hepatic failure including acute and/or fatal events, hepatic 
> cirrhosis, drug-induced liver injury 
> • Respiratory disorders: interstitial lung disease 
> • Metabolic and nutrition disorders: tumor lysis syndrome  
> • Immune system disorders: anaphylactic shock, angioedema, urticaria 
> • Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome (SJS), onychoclasis, 
> panniculitis, neutrophilic dermatoses, cutaneous vasculitis 
> • Infections: hepatitis B reactivation 
> • Nervous system disorders: peripheral neuropathy 
> • Eye disorders: uveitis”

Source: [IMBRUVICA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf#page=29)

## Related pages
- [Medical information: Imbruvica (ibrutinib): All indications](https://www.evicenter.com/medical-information/imbruvica)
- [Indication](https://www.evicenter.com/medical-information/imbruvica/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/imbruvica/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/imbruvica/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica/access-and-coverage)
